Intraocular pseudophakic contact lens (IOPCL) for treating age-related macular degeneration (AMD) or other eye disorders

Information

  • Patent Grant
  • 11938018
  • Patent Number
    11,938,018
  • Date Filed
    Thursday, May 27, 2021
    2 years ago
  • Date Issued
    Tuesday, March 26, 2024
    a month ago
  • Inventors
  • Original Assignees
    • OnPoint Vision, Inc. (Aliso Viejo, CA, US)
  • Examiners
    • Blanco; Javier G
Abstract
An apparatus includes an intraocular pseudophakic contact lens having an optical lens and haptics extending radially from the optical lens and configured to contact a capsular bag in an eye in order to secure the intraocular pseudophakic contact lens against an artificial intraocular lens. The optical lens includes a central portion and at least one annular portion surrounding the central portion, where the central and annular portions are configured to provide different optical powers. The central portion of the optical lens may be configured to provide an optical magnification, and the at least one annular portion of the optical lens may be configured to provide at least one different optical magnification or no optical magnification.
Description
TECHNICAL FIELD

This disclosure relates generally to optical systems. More specifically, this disclosure relates to an intraocular pseudophakic contact lens (IOPCL) for treating age-related macular degeneration (AMD) or other eye disorders.


BACKGROUND

Age-related macular degeneration (AMD) causes deterioration of the macula in the retina of an eye. The retina is a paper-thin tissue at the back of the eye where light-sensitive cells send visual signals to the brain, and the macula supports finely-detailed vision. Sharp, clear, straight-ahead vision is centered in the macula, and damage to the macula results in central blind spots of various sizes and blurred or distorted central vision. Those affected by AMD find many daily activities, such as driving and reading, increasingly difficult and eventually impossible as the disease progresses. Common difficulties and symptoms of AMD include loss of ability to drive a car, loss of ability to read, distortion or loss of central vision, progressive decrease in contrast sensitivity, increase in glare and light sensitivity, need for increased illumination to read, and impaired depth perception.


AMD is the leading cause of visual impairment and irreversible vision loss in the United States. AMD is more prevalent among people 50 years of age or older, and it is one of the leading causes of legal blindness. As many as 15 million Americans currently have some type of AMD, including both early and intermediate stages. This number is expected to increase to nearly 22 million by 2050. Worldwide, it is estimated that more than 196 million people suffer from some level of AMD and that this number will increase to 288 million by 2040. Risk factors for developing AMD include positive family history, cigarette smoking, hyperopia, lightly-pigmented eye population, hypertension, and cardiovascular disease.


SUMMARY

This disclosure provides an intraocular pseudophakic contact lens (IOPCL) for treating age-related macular degeneration (AMD) or other eye disorders.


In a first embodiment, an apparatus includes an intraocular pseudophakic contact lens having an optical lens and haptics extending radially from the optical lens and configured to contact a capsular bag in an eye in order to secure the intraocular pseudophakic contact lens against an artificial intraocular lens. The optical lens includes a central portion and at least one annular portion surrounding the central portion, where the central and annular portions are configured to provide different optical powers.


In a second embodiment, a system includes an artificial intraocular lens having a first optical lens and first haptics configured to be implanted within a capsular bag in an eye. The system also includes an intraocular pseudophakic contact lens having a second optical lens and second haptics extending radially from the second optical lens and configured to contact the capsular bag in order to secure the intraocular pseudophakic contact lens against the artificial intraocular lens. The second optical lens includes a central portion and at least one annular portion surrounding the central portion, where the central and annular portions are configured to provide different optical powers.


In a third embodiment, an apparatus includes an intraocular pseudophakic contact lens having an optical lens and haptics extending radially from the optical lens and configured to contact a capsular bag in an eye in order to secure the intraocular pseudophakic contact lens against an artificial intraocular lens. The optical lens includes a central portion and at least one annular portion surrounding the central portion, where the central and annular portions are configured to provide different optical powers. Anterior surfaces of the haptics include capsular wall-engaging surfaces configured to contact an inner capsular wall surface at an anterior leaflet of the capsular bag, where the capsular wall-engaging surfaces are configured to promote confinement, capture, or attachment of the haptics. Posterior surfaces of the haptics include ridges configured to capture at least one edge of the artificial intraocular lens. The haptics are flexible such that outer portions of the haptics are configured to drive the ridges into the at least one edge of the artificial intraocular lens based on surface pressure from an anterior leaflet of the capsular bag against the outer portions of the haptics. The central portion of the optical lens is configured to provide a central optical magnification, and the at least one annular portion of the optical lens is configured to provide at least one different optical magnification or no optical magnification.


Other technical features may be readily apparent to one skilled in the art from the following figures, descriptions, and claims.





BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of this disclosure and its features, reference is now made to the following description, taken in conjunction with the accompanying drawings, in which:



FIGS. 1 and 2 illustrate an example system for treating age-related macular degeneration (AMD) or other eye disorders according to this disclosure;



FIG. 3 illustrates a perspective view of an example intraocular pseudophakic contact lens for treating AMD or other eye disorders according to this disclosure;



FIG. 4 illustrates a top view of an example intraocular pseudophakic contact lens for treating AMD or other eye disorders according to this disclosure;



FIG. 5 illustrates a side view of an example intraocular pseudophakic contact lens for treating AMD or other eye disorders according to this disclosure;



FIGS. 6 and 7 illustrate different cross-sectional views of an example intraocular pseudophakic contact lens for treating AMD or other eye disorders according to this disclosure;



FIGS. 8 and 9 illustrate an example combination of an intraocular pseudophakic contact lens and an artificial intraocular lens that may be used for treating AMD or other eye disorders according to this disclosure;



FIGS. 10 through 12 illustrate an example coupling of an intraocular pseudophakic contact lens to an artificial intraocular lens for treating AMD or other eye disorders according to this disclosure; and



FIG. 13 illustrates an example method for treating AMD or other eye disorders according to this disclosure.





DETAILED DESCRIPTION


FIGS. 1 through 13, discussed below, and the various embodiments used to describe the principles of the present invention in this patent document are by way of illustration only and should not be construed in any way to limit the scope of the invention. Those skilled in the art will understand that the principles of the invention may be implemented in any type of suitably arranged device or system.


This disclosure relates to devices, systems, and techniques for treating age-related macular degeneration (AMD) or other types of eye disorders using an intraocular pseudophakic contact lens (IOPCL) that can be mounted on, attached to, or otherwise secured to an artificial intraocular lens (IOL) for each of one or more eyes of a patient. The intraocular pseudophakic contact lens includes an optical lens having different regions with different optical powers (refractive powers). For instance, the central region of the optical lens may provide a first amount of optical magnification (such as a high plus power optical magnification), and at least one annular region of the optical lens around the central region may provide at least one different amount of optical magnification (or no optical magnification). Among other things, this approach can be used to deliver a customized treatment for early and intermediate-stage AMD in pseudophakic patients. These patients may, for instance, have lost sufficient vision to support keeping their driving privileges. They may have also actually lost their drivers' licenses and/or the ability to read normal print.



FIGS. 1 and 2 illustrate an example system 100 for treating AMD or other eye disorders according to this disclosure. As shown in FIGS. 1 and 2, the system 100 is used in conjunction with an eye 102 of a patient. Depending on the circumstances, a single system 100 may be used with one eye 102 of the patient, or two systems 100 may be used with both eyes 102 of the patient. The eye 102 generally includes a cornea 104, a sclera 106, and an iris 108. The eye 102 itself is shown in cross-sectional form in FIG. 1 for ease of illustration and explanation. The cornea 104 represents the clear front portion of the eye 102 through which light passes to enter into the eye 102. The sclera 106 represents the tough outer white portion of the eye 102. The iris 108 represents the component of the eye 102 that controls the size of the eye's pupil to thereby control the amount of light from the cornea 104 that enters into the interior of the eye 102.


The eye 102 also includes a capsular bag 110, which typically holds the natural crystalline lens of the eye 102. However, in this example, the natural crystalline lens has been removed and replaced with an artificial intraocular lens (IOL) 112. The intraocular lens 112 generally includes an optical lens and one or more haptics. The optical lens of the intraocular lens 112 receives light entering the eye 102 and focuses the light onto the retina of the eye 102. The haptics of the intraocular lens 112 help to hold the intraocular lens 112 within the capsular bag 110 so that the optical lens of the intraocular lens 112 is in a desired position within the eye. An eye 102 in which the natural crystalline lens has been replaced with an artificial intraocular lens 112 is often referred to as a “pseudophakic” eye. Note that there are a wide variety of artificial intraocular lenses that may be used in a patient, and additional artificial intraocular lenses are sure to be developed in the future. The intraocular lens 112 shown here is for illustration only, and any other suitable artificial intraocular lens now known or later developed may be used in the system 100. Also, the intraocular lens 112 may be used here to provide any desired optical correction or other modification of light passing through the eye 102.


An intraocular pseudophakic contact lens (IOPCL) 114 has been placed on or otherwise in front of the intraocular lens 112 (possibly without touching the uveal tissue). The intraocular pseudophakic contact lens 114 represents an additional lens that can be mounted on, attached to, or otherwise secured to the intraocular lens 112. As shown here, the intraocular pseudophakic contact lens 114 may be placed on or in front of the anterior surface of the intraocular lens 112, meaning the front surface of the intraocular lens 112 with respect to the eye 102. Light enters through the cornea 104 and passes through the pupil before entering the intraocular pseudophakic contact lens 114, which modifies the light. The modified light then passes through the optical lens of the intraocular lens 112 and is again modified. The twice-modified light then travels through the remainder of the eye 102 to reach the retina at the back of the eye 102.


As described below, the intraocular pseudophakic contact lens 114 includes an optical lens and optionally a mechanism for securing the intraocular pseudophakic contact lens 114 to or against the intraocular lens 112. In some embodiments, for example, the intraocular pseudophakic contact lens 114 includes one or more haptics that extend a short distance and fit under an anterior leaflet of the capsular bag 110 in the eye 102. This allows the haptics to be captured and confined by the anterior leaflet and possibly attach to the capsular wall of the anterior leaflet via fibrosis or re-fibrosis. The anterior leaflet represents the outer portion of the front side of the capsular bag 110 that remains after an opening (referred to as a capsulorhexis) is formed in the capsular bag 110 so that the natural crystalline lens can be removed. The insertion of the haptics of the intraocular pseudophakic contact lens 114 under the anterior leaflet helps to secure the intraocular pseudophakic contact lens 114 in place. In some cases, the healing process in the eye 102 can cause fibrosis or re-fibrosis to occur, which could also attach the anterior leaflet to the haptics of the intraocular pseudophakic contact lens 114. In other embodiments, the intraocular pseudophakic contact lens 114 includes one or more pins that can pierce the lens material of the intraocular lens 112. In still other embodiments, the intraocular pseudophakic contact lens 114 may be designed to mate with or otherwise connect to one or more components of the intraocular lens 112 specifically designed for use with the intraocular pseudophakic contact lens 114. In general, any suitable mechanism(s) may be used to mount, attach, or otherwise secure the intraocular pseudophakic contact lens 114 in place relative to the intraocular lens 112.


Depending on the implementation, the intraocular pseudophakic contact lens 114 may be multi-focal and include a combination of lens powers, such as a high plus power optical segment and at least one other optical segment with a different power or no power. The desired optical powers of the intraocular pseudophakic contact lens 114 may be achieved in any suitable manner. For example, in some embodiments, the optical powers of the intraocular pseudophakic contact lens 114 could be delivered by varying one or both of the anterior and posterior sides of the optic in the intraocular pseudophakic contact lens 114.


While often described as being used to treat both eyes 102 of a patient, this is not necessarily required. For instance, a single eye 102 of a patient may be treated using an intraocular pseudophakic contact lens 114. The other eye 102 of the patient may or may not include an intraocular pseudophakic contact lens 114, and there is no requirement that the other eye 102 include the same type of intraocular pseudophakic contact lens 114. In general, the approaches described here can be easily customized to provide desired correction(s) of each patient's eye(s) 102 individually or collectively.


Although FIGS. 1 and 2 illustrate one example of a system 100 for treating AMD or other eye disorders, various changes may be made to FIGS. 1 and 2. For example, any suitable intraocular pseudophakic contact lens 114 and any suitable intraocular lens 112 may be used in the eye 102.



FIGS. 3 through 7 illustrate an example intraocular pseudophakic contact lens 300 for treating AMD or other eye disorders according to this disclosure. More specifically, FIG. 3 illustrates a perspective view of the intraocular pseudophakic contact lens 300, FIG. 4 illustrates a top view of the intraocular pseudophakic contact lens 300, and FIG. 5 illustrates a side view of the intraocular pseudophakic contact lens 300. FIGS. 6 and 7 illustrate different cross-sectional views of the intraocular pseudophakic contact lens 300. For ease of explanation, the intraocular pseudophakic contact lens 300 may be described as representing the intraocular pseudophakic contact lens 114 and as being used in the system 100 of FIGS. 1 and 2. However, the intraocular pseudophakic contact lens 300 may be used with any other suitable intraocular lens.


As shown in FIGS. 3 through 5, the intraocular pseudophakic contact lens 300 includes an optical lens 302, which denotes the portion of the intraocular pseudophakic contact lens 300 that alters light passing through the intraocular pseudophakic contact lens 300. For example, the light that passes through the optical lens 302 may then travel through an associated intraocular lens 112 before reaching the retina of a patient's eye 102. The optical lens 302 can be formed from any suitable material(s), such as silicone or acrylic. The optical lens 302 can also be formed in any suitable manner, such as by using a mold, laser, or lathe cut manufacturing process. Different optical lenses 302 in different intraocular pseudophakic contact lenses 300 can be designed and manufactured to provide different types of optical modifications, such as when different optical lenses 302 provide different amounts of optical magnification.


Multiple haptics 304a-304c extend from multiple sides of the optical lens 302. The haptics 304a-304c are sized and shaped so that they extend a short distance from the optical lens 302 and fit under the anterior leaflet of the capsular wall in a patient's eye 102 after implantation. Each haptic 304a-304c could be formed from any suitable material(s) and in any suitable manner. For example, each haptic 304a-304c could be formed from the same material(s) as the optical lens 302. Note that while three haptics 304a-304c are shown here, the intraocular pseudophakic contact lens 300 could include any number of haptics, including a single haptic. Also note that while the haptics 304a-304c angle downward (meaning the haptics 304a-304c generally extend outward and posteriorly from the optical lens 302), the haptics 304a-304c could have any other suitable arrangement. In addition, note that the haptics 304a-304c may be coupled to the optical lens 302 in any suitable manner, such as when the haptics 304a-304c are formed integral with the optical lens 302 or are attached to the optical lens 302 or to a retaining ring or other structure (integral with or attached to the optical lens 302) using adhesive or other suitable connecting mechanism.


Each of the haptics 304a-304c may include a textured surface 306, which may facilitate capture or confinement of the haptics 304a-304c by the anterior leaflet of the capsular wall in a patient's eye 102. Among other things, this can help the haptics 304a-304c to secure the intraocular pseudophakic contact lens 300 in place on or to the intraocular lens 112. In some cases, the textured surfaces 306 allow the haptics 304a-304c to actually physically bond to the anterior leaflet of the capsular wall in the patient's eye 102, such as through fibrosis or re-fibrosis during the healing process. In other cases, the textured surfaces 306 may simply resist movement of the haptics 304a-304c relative to the anterior leaflet of the capsular wall in the patient's eye 102.


Each textured surface 306 represents any suitable structure that facilitates confinement, capture, or attachment of the haptics 304a-304c by or to the anterior leaflet of the capsular wall. In some cases, each textured surface 306 may represent an electrical discharge machining (EDM) finish, or each textured surface 306 may represent holes formed partially or completely through the haptics 304a-304c (in which case the numbers and sizes of the holes in the textured surfaces 306 may vary as needed or desired). Note that other forms of texturing may be used here, or no texturing may be needed. Also note that the haptics 304a-304c may be omitted if not needed, such as when the intraocular pseudophakic contact lens 300 can be held in place on an intraocular lens 112 via surface tension, adhesive, or other technique. In addition, note that other types of haptics may be used with the intraocular pseudophakic contact lens 300, or pins embedded in or passing through projections from the optical lens of the intraocular pseudophakic contact lens 300 or other structures of the intraocular pseudophakic contact lens 300 may be used to secure the intraocular pseudophakic contact lens 300 to the intraocular lens 112. In general, this disclosure is not limited to any particular haptic design or mechanism for mounting or attaching the intraocular pseudophakic contact lens 300 on or to the intraocular lens 112.


In this example, the haptics 304a-304c of the intraocular pseudophakic contact lens 300 are formed as large projections that extend from the sides of the optical lens 302, effectively forming long “wings” extending from the optical lens 302. An inner portion of each haptic 304a-304c projects outward and downward (posteriorly) in this example, and an outer portion of each haptic 304a-304c projects outward and slightly upward in this example (although the outer portion of each haptic 304a-304c may be flexible as described below). Note, however, that other forms for the haptics 304a-304c could also be used. Each of the outer portions of the haptics 304a-304c has a thickness that tapers towards the outer edge of the haptic 304a-304c, which may facilitate easier insertion of the haptics 304a-304c under the anterior leaflet of the capsular wall in a patient's eye 102. The lower surfaces of the haptics 304a-304c also include ridges 308, and multiple ridges 308 of multiple haptics 304a-304c can be used to capture one or more edges of the underlying intraocular lens 112. This can help to center the intraocular pseudophakic contact lens 300 on the intraocular lens 112. This can also help to retain the intraocular pseudophakic contact lens 300 in place on the intraocular lens 112 during the healing process or otherwise during use. While the ridges 308 are shown here as being generally flat or slightly curved, the ridges 308 may incorporate other features. For instance, lips may be formed by small inward projections extending from the bottoms or other portion(s) of the ridges 308 inward towards a central optical axis of the optical lens 302 (meaning a vertical axis through the center of the optical lens 302 in FIG. 5).


The haptics 304a-304c may have any suitable positions in the intraocular pseudophakic contact lens 300. For example, in some embodiments, the haptics 304a-304c are evenly spaced about 120° apart. In other embodiments, the haptics 304a-304c are unevenly spaced, such as when the haptic 304a is separated from each of the haptics 304b-304c by about 125° and the haptics 304b-304c are separated from each other by about 110° (which may be based on, for instance, the positions of haptics of the intraocular lens 112 onto which the intraocular pseudophakic contact lens 300 will be placed). Also, in some cases, the intraocular pseudophakic contact lens 300 may be designed for implantation into a patient's eye 102 at a specific orientation, and at least one alignment marking 310 may be provided to identify proper orientation of the intraocular pseudophakic contact lens 300 in the eye 102. In this example, a single alignment marking 310 having the form of a raised letter “R” may be used, such as to identify the haptic 304a to be positioned on the right side of the intraocular lens 112 as the intraocular lens 112 within the eye 102 is viewed by a surgeon or other personnel. However, any other or additional alignment markings 310 or no alignment markings may be used here.


The optical lens 302 may have any suitable optical power(s) depending on the implementation. In this example, the optical lens 302 includes a first lens portion 312 and a second lens portion 314, where the two portions 312-314 of the optical lens 302 may provide different levels of optical magnification. For instance, the first lens portion 312 may provide a specified amount of magnification (such as a high plus power magnification), and the second lens portion 314 may provide a different amount of magnification or possibly little or no magnification. To provide a high plus power in this example, the anterior surface of the first lens portion 312 may be convex, and the posterior surface of the first lens portion 312 may be concave. The amount of high plus power magnification can be adjusted here by altering the shape of one or more of the anterior and posterior surfaces of the first lens portion 312. For instance, FIGS. 6 and 7 illustrate example cross-sections of the intraocular pseudophakic contact lens 300 taken along line A-A in FIG. 4, where different first lens portions 312a-312b are shown as having different shapes in their anterior surfaces. These different shapes allow the different first lens portions 312a-312b to provide different amounts of high plus power magnification. As a particular example, the lens portion 312a may provide an optical power of +11 diopters, and the lens portion 312b may provide an optical power of +5 diopters (although these are example values only).


As a result, the first lens portion 312 in the intraocular pseudophakic contact lens 300 can be used to provide a high amount of plus power optical magnification. This supports the use of the intraocular pseudophakic contact lens 300 in the system 100 to help treat conditions such as AMD or other vision loss related to retinal disease, where the magnification can help a patient perform tasks such as reading normal-sized print more easily or regaining his or her driving privileges. The second lens portion 314 in the intraocular pseudophakic contact lens 300 can be used to provide a different amount of optical magnification or no optical magnification. For instance, the anterior surface of the second lens portion 314 may be convex (with less convexity compared to the first lens portion 312), and the posterior surface of the second lens portion 314 may be concave.


In this particular example, the first lens portion 312 is generally circular and positioned centrally in the intraocular pseudophakic contact lens 300, and the second lens portion 314 is generally annular and surrounds the first lens portion 312. However, each lens portion 312 and 314 may have any other suitable size, shape, and position within the intraocular pseudophakic contact lens 300. In general, the sizes, shapes, and positions of the lens portions 312-314 can vary as needed or desired in order to provide the desired optical magnification(s).


The intraocular pseudophakic contact lens 300 shown in FIGS. 3 through 7 can be easily secured over an intraocular lens 112, such as by capturing and confining the haptics 304a-304c of the intraocular pseudophakic contact lens 300 using the anterior leaflet of the capsular wall in the eye 102. In some cases, this could also involve physical bonding of the haptics 304a-304c to the anterior leaflet of the capsular wall, such as via a fibrosis or re-fibrosis mechanism. Thus, in some embodiments, the intraocular pseudophakic contact lens 300 may not need to be designed to work specifically with particular structures of any specific intraocular lenses 112. Instead, the intraocular lens 112 being used with an intraocular pseudophakic contact lens 300 need not have any predefined structures that are provided for coupling to an intraocular pseudophakic contact lens 300. Rather, the intraocular pseudophakic contact lens 300 can simply be sized so that, when the intraocular pseudophakic contact lens 300 is placed on the intraocular lens 112, it can be secured in place through capture and confinement by (and possibly bonding with) the anterior leaflet of the capsular wall. This allows the intraocular pseudophakic contact lens 300 to be used with a wide variety of intraocular lenses 112, including different types of intraocular lenses 112 and including existing intraocular lenses 112 already implanted into patients. There is no need to remove an existing intraocular lens 112 from a patient in order to install a new intraocular lens and an intraocular pseudophakic contact lens. Note, however, that an intraocular pseudophakic contact lens may also be designed to specifically mate with a particular intraocular lens in other embodiments.


Moreover, the intraocular pseudophakic contact lens 300 could be easily removed from a patient's eyes 102, such as any suitable time after implantation or prior to bonding of the haptics 304a-304c to the capsular wall (assuming fibrosis or re-fibrosis holds the intraocular pseudophakic contact lens 300 in place). Among other things, this allows one intraocular pseudophakic contact lens 300 to be removed and replaced with a different intraocular pseudophakic contact lens 300 if a different optical magnification is needed or desired.


The intraocular pseudophakic contact lens 300 could have any suitable size, shape, and dimensions. For example, intraocular pseudophakic contact lenses 300 could be made available in a range of diameters from about 4 millimeters to about 6 millimeters. Also, the intraocular pseudophakic contact lenses 300 could be made available with varying base curvatures for their optical lenses 302. Of course, an intraocular pseudophakic contact lens 300 could also be custom designed for a particular patient's eye 102, such as when one or more specific curvatures are needed to provide a desired amount of optical magnification in the particular patient's eye 102.


In some embodiments, the intraocular pseudophakic contact lens 300 and various components of the intraocular pseudophakic contact lens 300 may have the following design parameters. The diameter of the first lens portion 312 may be about 1.8 millimeters, the diameter of the second lens portion 314 may be about 4.5 millimeters, the diameter of a circle defined by the ridges 308 may be about 6.05 millimeters, and the diameter of a circle defined by outer edges of the haptics 304a-304c may be about 7 millimeters. The straight edges of each haptic 304a-304c when viewed from the top may taper from a separation of about 0.97 millimeters to about 0.63 millimeters, where the straight edges define an angle of about 15°. The optical lens 302 may have a thickness along its outer edge of about 0.375 millimeters, and there may be a step of about 0.065 millimeters between the posterior surface of the optical lens 302 along its outer edge and posterior surfaces of the haptics 304a-304c. Each of the ridges 308 may form an angle of about 10° relative to a central optical axis of the optical lens 302, and the posterior surfaces of the haptics 304a-304c may extend from the optical lens 302 at an angle of about 103° relative to the central optical axis of the optical lens 302. The distance between the ridge 308 and the outer edge of each haptics 304a-304c may be about 0.48 millimeters. Various corners and edges of the intraocular pseudophakic contact lens 300 can be rounded, and the radii of curvatures of the anterior and posterior surfaces of the first and second lens portions 312-314 can vary based on the desired optical magnification(s) to be provided by the lens portions 312-314. Note, however, that these dimensions and other design parameters are for illustration only and can vary as needed or desired depending on the implementation of the intraocular pseudophakic contact lens 300.


The intraocular pseudophakic contact lens 300 can be implanted non-invasively in a patient's eye 102 and easily positioned on an intraocular lens 112. The implantation is non-invasive because the intraocular pseudophakic contact lens 300 is being installed on the anterior surface of an intraocular lens 112, which is typically easily accessible by a surgeon or other personnel during an implantation procedure. The implantation is also non-invasive because the intraocular pseudophakic contact lens 300 can be attached to the intraocular lens 112 without requiring attachment of the intraocular pseudophakic contact lens 300 to anatomical structures within the patient's eye 102, such as to the suculus of the patient's eye 102. The non-invasive implantation and easy positioning of an intraocular pseudophakic contact lens 300 provide a safe and effective surgical procedure to correct AMD or other eye disorders.


If the haptics 304a-304c of the intraocular pseudophakic contact lens 300 include ridges 308, the ridges 308 can be used to center the intraocular pseudophakic contact lens 300 on an underlying intraocular lens 112 as described above. If the intraocular pseudophakic contact lens 300 includes multiple haptics 304a-304c with associated ridges 308, the ridges 308 could help to perfectly center the intraocular pseudophakic contact lens 300 on the underlying intraocular lens 112. Such an approach allows the ridges 308 of the intraocular pseudophakic contact lens' haptics 304a-304c to capture the underlying intraocular lens 112 at the edge and perfectly line up the optical center of the intraocular pseudophakic contact lens' optic with the optical center of the intraocular lens 112. This alignment helps to reduce or avoid induced optical aberrations or induced prisms caused by optical center misalignment.


Note that in the above example, the intraocular pseudophakic contact lens 300 could possibly be designed so that only the haptics 304a-304c of the intraocular pseudophakic contact lens 300 extend under the anterior leaflet of the capsular wall in a patient's eye 102. This allows the haptics 304a-304c to be captured and confined by the anterior leaflet while leaving the optical lens 302 of the intraocular pseudophakic contact lens 300 free and generally unobscured by the surrounding tissue in the patient's eye 102.


Also note that, in some embodiments, the surgical tool disclosed in U.S. Patent Application Publication No. 2019/0269555 A1 (which is hereby incorporated by reference in its entirety) may be used to help implant an intraocular pseudophakic contact lens 300. For example, this tool may be used to separate at least part of the anterior leaflet of a patient's eye 102 from an implanted intraocular lens 112, allowing haptics 304a-304c of the intraocular pseudophakic contact lens 300 to be inserted between the anterior leaflet and the intraocular lens 112. As another example, this tool may be used to separate the anterior leaflet of a patient's eye 102 from an implanted intraocular pseudophakic contact lens, allowing the intraocular pseudophakic contact lens to be removed (and possibly replaced).


Although FIGS. 3 through 7 illustrate one example of an intraocular pseudophakic contact lens 300 for treating AMD or other eye disorders, various changes may be made to FIGS. 3 through 7. For example, the intraocular pseudophakic contact lens 300 could include any suitable number of each component shown in the figures. As a particular example, while the optical lens 302 is shown as having two portions 312 and 314, the optical lens 302 may have more than two regions (such as two or more annular regions around the central region). Also, the forms of the haptics 304a-304c shown here are examples only, and any other suitable structures or other mechanisms could be used to secure the intraocular pseudophakic contact lens 300 in place. Further, a number of other features could be used at one or more locations of the intraocular pseudophakic contact lenses 300. For instance, one or more drug-eluting materials could be placed on top, side, or bottom surfaces of the optical lenses in the intraocular pseudophakic contact lenses. Moreover, the specific dimensions, diopters, optical powers, and other values described above are for illustration only and do not limit this disclosure to the specific values.


In addition, the intraocular pseudophakic contact lens 300 shown in FIGS. 3 through 7 represents one example of the type of intraocular device that may be designed or modified for use in the system 100. However, various other intraocular devices may be designed or modified for use in the system 100. For example, U.S. Patent Application Publication No. 2020/0121446 A1 and U.S. Patent Application Publication No. 2019/0076237 A1 (both of which are hereby incorporated by reference in their entirety) disclose a number of intraocular pseudophakic contact lenses that include (or may be modified to include) optical lenses providing a central high plus power optical magnification, which would allow those intraocular pseudophakic contact lenses to be used in the system 100. Among other things, the intraocular pseudophakic contact lenses disclosed in the documents incorporated by reference above use pins, haptic loops, or other structures to secure the intraocular pseudophakic contact lenses to intraocular lenses, and any of these structures may be used with an intraocular pseudophakic contact lens as described above.



FIGS. 8 and 9 illustrate an example combination of an intraocular pseudophakic contact lens 300 and an artificial intraocular lens 112 that may be used for treating AMD or other eye disorders according to this disclosure. For ease of explanation, the combination may be described as being used in the system 100 of FIGS. 1 and 2. However, the system may use any other suitable combination of an intraocular pseudophakic contact lens and an intraocular lens.


As shown in FIGS. 8 and 9, the intraocular lens 112 includes an optical lens 802 and haptics 804 extending from the optical lens 802. The optical lens 802 receives light that has passed through the optical lens 302 of the intraocular pseudophakic contact lens 300 and focuses the light onto the retina of the eye 102. The haptics 804 help to hold the intraocular lens 112 within the capsular bag 110 so that the optical lens 802 is in a desired position within the eye 102. Note that the forms of the optical lens 802 and the haptics 804 shown here are examples only and that other intraocular lens may include different optical lenses or different haptics. For instance, the haptics of the intraocular lens 112 in FIGS. 1 and 2 take the form of loops rather than arms as in FIGS. 8 and 9.



FIGS. 10 through 12 illustrate an example coupling of an intraocular pseudophakic contact lens 300 to an artificial intraocular lens 112 for treating AMD or other eye disorders according to this disclosure. For ease of explanation, the coupling may be described as being performed to help form the system 100 of FIGS. 1 and 2. However, the coupling may involve any other suitable intraocular pseudophakic contact lens and any other suitable intraocular lens.


As shown in FIG. 10, the intraocular pseudophakic contact lens 300 and the intraocular lens 112 are shown in side profile, and the intraocular pseudophakic contact lens 300 is being moved towards the intraocular lens 112. An outer portion 1002 of each haptic 304a-304c angles partially upward here, which facilitates coupling of the intraocular pseudophakic contact lens 300 to the intraocular lens 112 as described below. The intraocular pseudophakic contact lens 300 can be moved towards the intraocular lens 112 in any suitable manner, such as when a surgeon or other personnel uses a tool to grasp and manipulate the intraocular pseudophakic contact lens 300.


As shown in FIG. 11, the intraocular pseudophakic contact lens 300 is being placed onto the anterior surface of the intraocular lens 112. However, in FIG. 11, it is assumed that the outer portions 1002 of the haptics 304a-304c have not been placed under the anterior leaflet in the eye 102, which is why the outer portions 1002 of the haptics 304a-304c still angle partially upward here. This allows the ridges 308 of the haptics 304a-304c to more easily surround and capture the outer edge of the optical lens 802 of the intraocular lens 112.


As shown in FIG. 12, the intraocular pseudophakic contact lens 300 has now been secured to the anterior surface of the intraocular lens 112. In FIG. 12, it is assumed that the outer portions 1002 of the haptics 304a-304c have been placed under the anterior leaflet in the eye 102. The anterior leaflet applies a downward force to the outer portions 1002 of the haptics 304a-304c. Assuming the haptics 304a-304c are flexible, this surface pressure causes the outer portions 1002 of the haptics 304a-304c to deflect and angle partially downward, which helps to drive the ridges 308 (and optionally any lips or other structures on the ridges 308) into the outer edge of the optical lens 802 of the intraocular lens 112. This helps to secure the intraocular pseudophakic contact lens 300 to the intraocular lens 112 and helps to align the optical axes of the intraocular pseudophakic contact lens 300 and the intraocular lens 112.


Although FIGS. 8 and 9 illustrate one example of a combination of an intraocular pseudophakic contact lens 300 and an artificial intraocular lens 112 that may be used to treat AMD or other eye disorders and FIGS. 10 through 12 illustrate one example of a coupling of an intraocular pseudophakic contact lens 300 to an artificial intraocular lens 112 to treat AMD or other eye disorders, various changes may be made to FIGS. 8 through 12. For example, any other suitable mechanism (possibly including just surface tension) may be used to hold the intraocular pseudophakic contact lens on or against the intraocular lens.



FIG. 13 illustrates an example method 1300 for treating AMD or other eye disorders according to this disclosure. For ease of explanation, the method 1300 is described as using the intraocular pseudophakic contact lens 300 as part of the formation of the system 100. However, the method 1300 may use any other suitable intraocular pseudophakic contact lens.


As shown in FIG. 13, an intraocular pseudophakic contact lens (IOPCL) providing a desired amount of optical magnification is selected at step 1302 and inserted into a patient's eye at step 1304. This may include, for example, a surgeon or other personnel selecting an intraocular pseudophakic contact lens 300 that provides a desired amount of high plus power optical magnification, such as from a kit. This may also include the surgeon or other personnel forming a small incision in the patient's eye 102 and inserting the intraocular pseudophakic contact lens 300 into the eye 102 through the incision. The intraocular pseudophakic contact lens 300 can be rolled, folded, or otherwise reduced in cross-sectional size in order to insert the intraocular pseudophakic contact lens 300 through a smaller incision.


The intraocular pseudophakic contact lens is secured against an intraocular lens in the patient's eye at step 1306. In some embodiments, this may include, for example, one or more haptics 304a-304c of the intraocular pseudophakic contact lens 300 sliding or otherwise being inserted under the anterior leaflet of the capsular wall in the patient's eye 102. In other embodiments, this may include one or more pins of the intraocular pseudophakic contact lens 300 piercing the lens material of the optical lens 802 in the intraocular lens 112. Any other suitable mechanism may be used here to secure the intraocular pseudophakic contact lens 300 against the intraocular lens 112. The intraocular pseudophakic contact lens is used to provide optical magnification in the patient's eye at step 1308. This may include, for example, the first lens portion 312 of the intraocular pseudophakic contact lens 300 providing high plus power magnification during use of the intraocular pseudophakic contact lens 300.


Although FIG. 13 illustrates one example of a method 1300 for treating AMD or other eye disorders, various changes may be made to FIG. 13. For example, while shown as a series of steps, various steps in FIG. 13 could overlap, occur in parallel, occur in a different order, or occur any number of times.


It may be advantageous to set forth definitions of certain words and phrases used throughout this patent document. The terms “include” and “comprise,” as well as derivatives thereof, mean inclusion without limitation. The term “or” is inclusive, meaning and/or. The phrase “associated with,” as well as derivatives thereof, may mean to include, be included within, interconnect with, contain, be contained within, connect to or with, couple to or with, be communicable with, cooperate with, interleave, juxtapose, be proximate to, be bound to or with, have, have a property of, have a relationship to or with, or the like. The phrase “at least one of,” when used with a list of items, means that different combinations of one or more of the listed items may be used, and only one item in the list may be needed. For example, “at least one of: A, B, and C” includes any of the following combinations: A, B, C, A and B, A and C, B and C, and A and B and C.


The description in this patent document should not be read as implying that any particular element, step, or function is an essential or critical element that must be included in the claim scope. Also, none of the claims is intended to invoke 35 U.S.C. § 112(f) with respect to any of the appended claims or claim elements unless the exact words “means for” or “step for” are explicitly used in the particular claim, followed by a participle phrase identifying a function. Use of terms such as (but not limited to) “mechanism,” “module,” “device,” “unit,” “component,” “element,” “member,” “apparatus,” “machine,” “system,” “processor,” “processing device,” or “controller” within a claim is understood and intended to refer to structures known to those skilled in the relevant art, as further modified or enhanced by the features of the claims themselves, and is not intended to invoke 35 U.S.C. § 112(f).


While this disclosure has described certain embodiments and generally associated methods, alterations and permutations of these embodiments and methods will be apparent to those skilled in the art. Accordingly, the above description of example embodiments does not define or constrain this disclosure. Other changes, substitutions, and alterations are also possible without departing from the spirit and scope of this disclosure, as defined by the following claims.

Claims
  • 1. An apparatus comprising: an intraocular pseudophakic contact lens comprising: an optical lens; andhaptics extending radially from the optical lens and configured to contact a capsular bag in an eye in order to secure the intraocular pseudophakic contact lens against an artificial intraocular lens;wherein the optical lens comprises a central portion and at least one annular portion surrounding the central portion, the central and annular portions configured to provide different optical powers;wherein anterior surfaces of the haptics comprise capsular wall-engaging surfaces configured to contact an inner capsular wall surface at an anterior leaflet of the capsular bag, the capsular wall-engaging surfaces configured to promote confinement, capture, or attachment of the haptics;wherein posterior surfaces of the haptics comprise ridges configured to capture at least one edge of the artificial intraocular lens; andwherein the haptics are flexible such that outer portions of the haptics are configured to drive the ridges into the at least one edge of the artificial intraocular lens based on surface pressure from the anterior leaflet of the capsular bag against the outer portions of the haptics.
  • 2. The apparatus of claim 1, wherein: the central portion of the optical lens is configured to provide a central optical magnification; andthe at least one annular portion of the optical lens is configured to provide no optical magnification.
  • 3. The apparatus of claim 2, wherein: the central portion of the optical lens comprises a convex anterior surface and a concave posterior surface; andeach annular portion of the optical lens comprises a convex anterior surface and a concave posterior surface.
  • 4. The apparatus of claim 1, wherein one of the haptics comprises an alignment marking identifying a desired orientation of the intraocular pseudophakic contact lens in the eye.
  • 5. The apparatus of claim 1, wherein the central portion of the optical lens is configured to provide an optical power of about +5 diopters to about +11 diopters.
  • 6. The apparatus of claim 1, wherein: the central portion of the optical lens is configured to provide a central optical magnification; andthe at least one annular portion of the optical lens is configured to provide at least one different optical magnification.
  • 7. The apparatus of claim 6, wherein: the central portion of the optical lens comprises a convex anterior surface and a concave posterior surface; andeach annular portion of the optical lens comprises a convex anterior surface and a concave posterior surface.
  • 8. The apparatus of claim 7, wherein a convexity of the convex anterior surface of the central portion is greater than a convexity of the convex anterior surface of each annular portion.
  • 9. The apparatus of claim 1, wherein the haptics comprise three haptics configured to center the intraocular pseudophakic contact lens on the artificial intraocular lens.
  • 10. A system comprising: an artificial intraocular lens comprising a first optical lens and first haptics configured to be implanted within a capsular bag in an eye; andan intraocular pseudophakic contact lens comprising: a second optical lens; andsecond haptics extending radially from the second optical lens and configured to contact the capsular bag in order to secure the intraocular pseudophakic contact lens against the artificial intraocular lens;wherein the second optical lens comprises a central portion and at least one annular portion surrounding the central portion, the central and annular portions configured to provide different optical powers;wherein anterior surfaces of the second haptics comprise capsular wall-engaging surfaces configured to contact an inner capsular wall surface at an anterior leaflet of the capsular bag, the capsular wall-engaging surfaces configured to promote confinement, capture, or attachment of the second haptics;wherein posterior surfaces of the second haptics comprise ridges configured to capture at least one edge of the artificial intraocular lens; andwherein the second haptics are flexible such that outer portions of the second haptics are configured to drive the ridges into the at least one edge of the artificial intraocular lens based on surface pressure from the anterior leaflet of the capsular bag against the outer portions of the second haptics.
  • 11. The system of claim 10, wherein: the central portion of the second optical lens is configured to provide a central optical magnification; andthe at least one annular portion of the second optical lens is configured to provide no optical magnification.
  • 12. The system of claim 11, wherein: the central portion of the second optical lens comprises a convex anterior surface and a concave posterior surface; andeach annular portion of the second optical lens comprises a convex anterior surface and a concave posterior surface.
  • 13. The system of claim 10, wherein one of the second haptics comprises an alignment marking identifying a desired orientation of the intraocular pseudophakic contact lens in the eye.
  • 14. The system of claim 10, wherein the central portion of the second optical lens is configured to provide an optical power of about +5 diopters to about +11 diopters.
  • 15. The system of claim 10, wherein: the central portion of the second optical lens is configured to provide a central optical magnification; andthe at least one annular portion of the second optical lens is configured to provide at least one different optical magnification.
  • 16. The system of claim 15, wherein: the central portion of the second optical lens comprises a convex anterior surface and a concave posterior surface; andeach annular portion of the second optical lens comprises a convex anterior surface and a concave posterior surface.
  • 17. The system of claim 16, wherein a convexity of the convex anterior surface of the central portion is greater than a convexity of the convex anterior surface of each annular portion.
  • 18. The system of claim 10, wherein the second haptics comprise three haptics configured to center the intraocular pseudophakic contact lens on the artificial intraocular lens.
  • 19. The system of claim 10, wherein the second haptics are shorter than the first haptics.
  • 20. An apparatus comprising: an intraocular pseudophakic contact lens comprising: an optical lens; andhaptics extending radially from the optical lens and configured to contact a capsular bag in an eye in order to secure the intraocular pseudophakic contact lens against an artificial intraocular lens;wherein the optical lens comprises a central portion and at least one annular portion surrounding the central portion, the central and annular portions configured to provide different optical powers;wherein anterior surfaces of the haptics comprise capsular wall-engaging surfaces configured to contact an inner capsular wall surface at an anterior leaflet of the capsular bag, the capsular wall-engaging surfaces configured to promote confinement, capture, or attachment of the haptics;wherein posterior surfaces of the haptics comprise ridges configured to capture at least one edge of the artificial intraocular lens;wherein the haptics are flexible such that outer portions of the haptics are configured to drive the ridges into the at least one edge of the artificial intraocular lens based on surface pressure from the anterior leaflet of the capsular bag against the outer portions of the haptics;wherein the central portion of the optical lens is configured to provide a central optical magnification; andwherein the at least one annular portion of the optical lens is configured to provide at least one different optical magnification or no optical magnification.
CROSS-REFERENCE TO RELATED APPLICATIONS AND PRIORITY CLAIM

This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 63/057,738 filed on Jul. 28, 2020. This application also claims priority under 35 U.S.C. § 120 as a continuation-in-part of U.S. patent application Ser. No. 17/011,975 filed on Sep. 3, 2020, which is a continuation of U.S. patent application Ser. No. 16/190,959 filed on Nov. 14, 2018 (now U.S. Pat. No. 10,842,614), which is a continuation of U.S. patent application Ser. No. 14/860,629 filed on Sep. 21, 2015 (now U.S. Pat. No. 10,159,562), which claims priority under U.S.C. § 119(e) to U.S. Provisional Patent Application No. 62/053,771 filed on Sep. 22, 2014. This application further claims priority under 35 U.S.C. § 120 as a continuation-in-part of U.S. patent application Ser. No. 16/717,304 filed on Dec. 17, 2019, which is a continuation-in-part of U.S. patent application Ser. No. 16/398,627 filed on Apr. 30, 2019 (now U.S. Pat. No. 10,945,832), which is a continuation-in-part of U.S. patent application Ser. No. 15/646,254 filed on Jul. 11, 2017 (now U.S. Pat. No. 10,299,910), which is a continuation-in-part of U.S. patent application Ser. No. 14/860,629 filed on Sep. 21, 2015 (now U.S. Pat. No. 10,159,562), which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 62/053,771 filed on Sep. 22, 2014. All of these applications are hereby incorporated by reference in their entirety.

US Referenced Citations (262)
Number Name Date Kind
4124905 Clark Nov 1978 A
4932971 Kelman Jun 1990 A
5071432 Baikoff Dec 1991 A
5078742 Dahan Jan 1992 A
5098444 Feaster Mar 1992 A
5133747 Feaster Jul 1992 A
5201762 Hauber Apr 1993 A
5217491 Vanderbilt Jun 1993 A
5266241 Parekh Nov 1993 A
5275623 Sarfarazi Jan 1994 A
5354334 Fedorov et al. Oct 1994 A
5358520 Patel Oct 1994 A
5443506 Garabet Aug 1995 A
5443507 Jacobi Aug 1995 A
5522891 Klaas Jun 1996 A
5539016 Kunzier et al. Jul 1996 A
5684560 Roffman et al. Nov 1997 A
5693095 Freeman et al. Dec 1997 A
5699142 Lee et al. Dec 1997 A
5728156 Gupta Mar 1998 A
5755786 Woffinden et al. May 1998 A
5769890 McDonald Jun 1998 A
5782911 Herrick Jul 1998 A
5814103 Lipshitz et al. Sep 1998 A
5824074 Koch Oct 1998 A
6027531 Tassignon Feb 2000 A
6030416 Huo et al. Feb 2000 A
6045577 Woffinden et al. Apr 2000 A
6113633 Portney Sep 2000 A
6142625 Sawano et al. Nov 2000 A
6169127 Lohmann et al. Jan 2001 B1
6197057 Peyman et al. Mar 2001 B1
6200342 Tassignon Mar 2001 B1
6217171 Auten et al. Apr 2001 B1
6217612 Woods Apr 2001 B1
6197058 Portney Jun 2001 B1
6277146 Peyman et al. Aug 2001 B1
6419697 Kelman Jul 2002 B1
6454801 Portney Sep 2002 B1
6464725 Skotton Oct 2002 B2
6488708 Sarfarazi Dec 2002 B2
6554859 Lang et al. Apr 2003 B1
6554860 Hoffmann et al. Apr 2003 B2
6558420 Green May 2003 B2
6582076 Roffman et al. Jun 2003 B1
6616691 Tran Sep 2003 B1
6616692 Glick et al. Sep 2003 B1
6645246 Weinschenk, III et al. Nov 2003 B1
6705729 Piers et al. Mar 2004 B2
6749634 Hanna Jun 2004 B2
6767363 Bandhauer et al. Jul 2004 B1
6797004 Brady et al. Sep 2004 B1
6818017 Shu Nov 2004 B1
6827738 Willis et al. Dec 2004 B2
6851803 Wooley et al. Feb 2005 B2
6860601 Shadduck Mar 2005 B2
6880558 Perez Apr 2005 B2
6926736 Peng et al. Aug 2005 B2
6952313 Schrader Oct 2005 B2
6960230 Haefliger Nov 2005 B2
6960231 Tran Nov 2005 B2
6991651 Portney Jan 2006 B2
7008448 Lipshitz et al. Mar 2006 B2
7008449 Willis et al. Mar 2006 B2
7029497 Zhang et al. Apr 2006 B2
7036931 Lindacher et al. May 2006 B2
7081134 Cukrowski Jul 2006 B2
7101397 Aharoni Sep 2006 B2
7111938 Andino et al. Sep 2006 B2
7118597 Miller et al. Oct 2006 B2
7150760 Zhang Dec 2006 B2
7186266 Peyman Mar 2007 B2
7220278 Peyman May 2007 B2
7223288 Zhang et al. May 2007 B2
7238201 Portney et al. Jun 2007 B2
7279006 Vincent Oct 2007 B2
7311194 Jin et al. Dec 2007 B2
7316713 Zhang Jan 2008 B2
7338161 Chauveau et al. Mar 2008 B2
7452378 Zadno-Azizi et al. Nov 2008 B2
7453646 Lo Nov 2008 B2
7462193 Nagamoto Dec 2008 B2
7572007 Simpson Aug 2009 B2
7591849 Richardson Sep 2009 B2
7604349 Blum et al. Oct 2009 B2
7744647 Barrett Jun 2010 B2
7794498 Pinchuk Sep 2010 B2
7806929 Brown Oct 2010 B2
7842087 Ben Nun Nov 2010 B2
7871162 Weeber Jan 2011 B2
7871437 Hermans et al. Jan 2011 B2
7875661 Salamone Jan 2011 B2
7892264 Sanders et al. Feb 2011 B2
7905917 Altmann Mar 2011 B2
7918886 Aharoni et al. Apr 2011 B2
7942929 Linhardt et al. May 2011 B2
7955704 Lowery et al. Jun 2011 B2
8012204 Weinschenk, III et al. Sep 2011 B2
8034107 Stenger Oct 2011 B2
8109999 Hampp Feb 2012 B2
8133274 Zhou et al. Mar 2012 B2
8197541 Schedler Jun 2012 B2
8222360 Liao Jul 2012 B2
8231219 Weeber Jul 2012 B2
8273123 Ben Nun Sep 2012 B2
8324256 Domschke et al. Dec 2012 B2
8337552 Kobayashi et al. Dec 2012 B2
8377124 Hong et al. Feb 2013 B2
8419791 Toop Apr 2013 B2
8430928 Liao Apr 2013 B2
8491651 Tsai et al. Jul 2013 B2
8523942 Cumming Sep 2013 B2
8530590 Hu et al. Sep 2013 B2
8579972 Rombach Nov 2013 B2
8603167 Rombach Dec 2013 B2
8608799 Blake Dec 2013 B2
8636358 Binder Jan 2014 B2
8680172 Liao Mar 2014 B2
8696746 Wanders et al. Apr 2014 B2
8834566 Jones Sep 2014 B1
8852274 Doraiswamy et al. Oct 2014 B2
8858626 Noy Oct 2014 B2
8920495 Mirlay Dec 2014 B2
8945213 Terwee et al. Feb 2015 B2
8968399 Ghabra Mar 2015 B2
8992611 Zhao Mar 2015 B2
D729390 Doraiswamy et al. May 2015 S
9039760 Brady et al. May 2015 B2
9072600 Tran Jul 2015 B2
9084674 Brady et al. Jul 2015 B2
D738947 Litovchenko Sep 2015 S
9237946 Pynson Jan 2016 B2
9304329 Zhao Apr 2016 B2
9329410 Riall et al. May 2016 B2
9387069 Kahook et al. Jul 2016 B2
9445892 Brown Sep 2016 B2
9554893 Brady et al. Jan 2017 B2
9675445 Moriarty Jun 2017 B2
9757228 Wanders et al. Sep 2017 B2
9808339 Dorronsoro Diaz et al. Nov 2017 B2
9820849 Jansen Nov 2017 B2
9848980 McCafferty Dec 2017 B2
9869885 De Sio et al. Jan 2018 B2
9931202 Borja et al. Apr 2018 B2
9937034 Wanders Apr 2018 B2
10004592 Amon Jun 2018 B2
10004596 Brady et al. Jun 2018 B2
10028824 Kahook et al. Jul 2018 B2
10299910 Cady May 2019 B2
10842614 Cady Nov 2020 B2
11083622 Cady et al. Aug 2021 B2
11109957 Cady Sep 2021 B2
20020120329 Lang et al. Aug 2002 A1
20020161436 Portney Oct 2002 A1
20030158560 Portney Aug 2003 A1
20030187504 Weinschenk, III et al. Oct 2003 A1
20030220687 Nordan et al. Nov 2003 A1
20040106993 Portney Jun 2004 A1
20040158322 Shen Aug 2004 A1
20040167621 Peyman Aug 2004 A1
20040236422 Zhang et al. Nov 2004 A1
20040249455 Tran Dec 2004 A1
20050027354 Brady et al. Feb 2005 A1
20050060032 Magnante et al. Mar 2005 A1
20050113913 Duvert May 2005 A1
20060001186 Richardson et al. Jan 2006 A1
20060047339 Brown Mar 2006 A1
20060058874 Peli Mar 2006 A1
20060142856 Willis et al. Jun 2006 A1
20060184244 Nguyen et al. Aug 2006 A1
20060241752 Israel Oct 2006 A1
20060253196 Woods Nov 2006 A1
20060265059 Sunada et al. Nov 2006 A1
20070010881 Soye et al. Jan 2007 A1
20070016293 Tran Jan 2007 A1
20070021832 Nordan Jan 2007 A1
20070032866 Portney Feb 2007 A1
20070118216 Pynson May 2007 A1
20070260308 Tran Nov 2007 A1
20070260309 Richardson Nov 2007 A1
20070270947 Peyman Nov 2007 A1
20070282438 Hong et al. Dec 2007 A1
20080046077 Cumming Feb 2008 A1
20080051886 Lin Feb 2008 A1
20080086208 Nordan Apr 2008 A1
20080103592 Maloney May 2008 A1
20080147085 Gardeski et al. Jun 2008 A1
20080208334 Jinkerson et al. Aug 2008 A1
20080208335 Blum Aug 2008 A1
20080215147 Werblin Sep 2008 A1
20080281414 Akahoshi Nov 2008 A1
20080288066 Cumming Nov 2008 A1
20080312738 Wanders Dec 2008 A1
20090048671 Lipshitz et al. Feb 2009 A1
20090062911 Bogaert Mar 2009 A1
20090130176 Bossy-Nobs et al. May 2009 A1
20090182422 Nordan et al. Jul 2009 A1
20090198326 Zhou et al. Aug 2009 A1
20100004742 Cumming Jan 2010 A1
20100016965 Hong et al. Jan 2010 A1
20100036488 de Juan, Jr. et al. Feb 2010 A1
20100094412 Wensrich Apr 2010 A1
20100094413 Rombach et al. Apr 2010 A1
20100131061 Callahan et al. May 2010 A1
20100161048 Schaper, Jr. Jun 2010 A1
20100161050 Detmers et al. Jun 2010 A1
20100211171 Sarfarazi Aug 2010 A1
20100280609 Simonov et al. Nov 2010 A1
20100292789 Willis et al. Nov 2010 A1
20110021733 Wanders et al. Jan 2011 A1
20110153014 Zhang et al. Jun 2011 A1
20110251686 Masket Oct 2011 A1
20110313520 Shoji et al. Dec 2011 A1
20110313521 Angelopoulos Dec 2011 A1
20110313522 Hayes Dec 2011 A1
20110313523 Hayes Dec 2011 A1
20120109294 Olson May 2012 A1
20120232649 Cuevas Sep 2012 A1
20120253459 Reich et al. Oct 2012 A1
20120323321 Simonov et al. Dec 2012 A1
20130066422 Dworschak et al. Mar 2013 A1
20130110234 DeVita et al. May 2013 A1
20130110235 Schwiegerling May 2013 A1
20130131796 Mirlay May 2013 A1
20130190868 Kahook et al. Jul 2013 A1
20130197636 Haefliger Aug 2013 A1
20130204364 Olson Aug 2013 A1
20130238091 Danta et al. Sep 2013 A1
20130253159 Benz et al. Sep 2013 A1
20130304206 Pallikaris et al. Nov 2013 A1
20130317607 Deboer et al. Nov 2013 A1
20130338767 Mazzocchi et al. Dec 2013 A1
20140052246 Kahook et al. Feb 2014 A1
20140058507 Reich et al. Feb 2014 A1
20140121768 Simpson May 2014 A1
20140180404 Tran Jun 2014 A1
20140180406 Simpson Jun 2014 A1
20140228949 Argento et al. Aug 2014 A1
20140240657 Pugh et al. Aug 2014 A1
20140243972 Wanders Aug 2014 A1
20140253877 Li et al. Sep 2014 A1
20140277434 Weeber et al. Sep 2014 A1
20140330375 McCafferty Nov 2014 A1
20140330376 Kleinman Nov 2014 A1
20140347624 Ando et al. Nov 2014 A1
20140368789 Webb Dec 2014 A1
20150230981 Kahook et al. Aug 2015 A1
20150297342 Rosen et al. Oct 2015 A1
20160000558 Honigsbaum Jan 2016 A1
20160008126 Salahieh et al. Jan 2016 A1
20160081791 Cady Mar 2016 A1
20160199176 Wanders Jul 2016 A1
20160256265 Borja et al. Sep 2016 A1
20160317286 Brady et al. Nov 2016 A1
20160334643 Hyde et al. Nov 2016 A1
20170172733 Scharioth et al. Jun 2017 A1
20170296331 Werblin et al. Oct 2017 A1
20170304045 Cady Oct 2017 A1
20190254808 Cady Aug 2019 A1
20200397562 Cady Dec 2020 A1
20210186681 Qureshi et al. Jun 2021 A1
20210290369 Cady Sep 2021 A1
Foreign Referenced Citations (95)
Number Date Country
2014202532 Jul 2014 AU
PI1005015 Apr 2013 BR
102012000755 Oct 2013 BR
2717403 Aug 2005 CN
201015617 Feb 2008 CN
203425064 Feb 2014 CN
19501444 Jul 1996 DE
20109306 Aug 2001 DE
10025320 Nov 2001 DE
102007002885 Jul 2008 DE
202010002895 May 2010 DE
202013009162 Nov 2013 DE
0760232 Mar 1997 EP
1369710 Dec 2003 EP
1449498 Aug 2004 EP
1493405 Jan 2005 EP
1504730 Feb 2005 EP
1658828 May 2006 EP
2666735 Mar 1992 FR
2869793 Nov 2005 FR
2966340 Apr 2012 FR
2998474 May 2014 FR
2464505 Apr 2010 GB
2517531 Feb 2015 GB
H07255757 Oct 1995 JP
2002360616 Dec 2002 JP
2004528065 Sep 2004 JP
4199573 Oct 2004 JP
2006511242 Apr 2006 JP
4363573 Nov 2009 JP
4431372 Mar 2010 JP
5398089 Jun 2013 JP
2013528098 Jul 2013 JP
5383782 Jan 2014 JP
2016534816 Nov 2016 JP
2017528300 Sep 2017 JP
2020526336 Aug 2020 JP
101555298 Sep 2015 KR
102569508 Aug 2023 KR
2045246 Oct 1995 RU
2080100 Aug 1996 RU
2070004 Dec 1996 RU
2129880 May 1999 RU
2134086 Aug 1999 RU
31954 Sep 2003 RU
2234417 Aug 2004 RU
47696 Sep 2005 RU
2281063 Aug 2006 RU
2281067 Aug 2006 RU
2281726 Aug 2006 RU
2283067 Sep 2006 RU
2288494 Nov 2006 RU
2377964 Jan 2010 RU
2457811 Aug 2012 RU
2479286 Apr 2013 RU
2531472 Oct 2014 RU
M329428 Apr 2008 TW
201103517 Feb 2011 TW
8909576 Oct 1989 WO
9113597 Sep 1991 WO
9215260 Sep 1992 WO
9407435 Apr 1994 WO
9413225 Jun 1994 WO
9605047 Feb 1996 WO
9712564 Apr 1997 WO
9918457 Apr 1999 WO
9935520 Jul 1999 WO
9956671 Nov 1999 WO
9962434 Dec 1999 WO
0048491 Aug 2000 WO
0108605 Feb 2001 WO
0115635 Mar 2001 WO
0187182 Nov 2001 WO
2005104994 Nov 2005 WO
2006025726 Mar 2006 WO
2006119016 Nov 2006 WO
2007138564 Dec 2007 WO
2008094518 Aug 2008 WO
2010095938 Aug 2010 WO
2010131955 Nov 2010 WO
2011115860 Sep 2011 WO
2012054402 Apr 2012 WO
2013055212 Apr 2013 WO
2013169652 Nov 2013 WO
2014058315 Apr 2014 WO
2014058316 Apr 2014 WO
2014071532 May 2014 WO
2014099338 Jun 2014 WO
2014108100 Jul 2014 WO
2015006839 Jan 2015 WO
2015022514 Feb 2015 WO
2015026226 Feb 2015 WO
2015037994 Mar 2015 WO
2015044235 Apr 2015 WO
2015066502 May 2015 WO
Non-Patent Literature Citations (41)
Entry
Grant of Patent dated Jan. 17, 2022 in connection with Korean Patent Application No. 10-2021-7018671, 7 pages.
“1/1-Designs—Questel”, May 2018, 3 pages.
“1/1-Designs—Questel”, May 2018, 4 pages.
Extended European Search Report and Written Opinion for European U.S. Appl. No. 15/845,158 dated Mar. 6, 2018, 9 pages.
International Search Report and Written Opinion of the International Searching Authority dated Aug. 30, 2018 in connection with International Patent Application No. PCT/US2018/36519, 13 pages.
International Search Report and Written Opinion of the International Searching Authority dated Dec. 21, 2015 in connection with International Patent Application No. PCT/US2015/051415, 9 pages.
Office Action dated Jun. 24, 2019 in connection with New Zealand Patent Application No. 729994, 3 pages.
Office Action dated Aug. 1, 2019 in connection with Japanese Patent Application No. 2017-535622, 11 pages.
Office Action in connection with Australian Patent Application No. 2019204613 dated Nov. 22, 2019, 3 pages.
Office Action dated Jul. 29, 2020 in connection with Australian Patent Application No. 2019204613, 3 pages.
Office Action dated May 20, 2020 in connection with Australian Patent Application No. 2018301248, 3 pages.
Communication pursuant to Article 94(3) EPC dated Jul. 15, 2020 in connection with European Patent Application No. 15845158.3, 6 pages.
Office Action dated Aug. 3, 2020 in connection with U.S. Appl. No. 16/398,627, 78 pages.
Supplementary European Search Report dated Oct. 28, 2020 in connection with European Patent Application No. 18831320, 7 pages.
Communication pursuant to Rules 70(2) and 70a(2) EPC dated Nov. 17, 2020 in connection with European Patent Application No. 18831320, 1 page.
Office Action dated Jan. 5, 2021 in connection with Japanese Patent Application No. 2020-066515, 4 pages.
Office Action dated Mar. 19, 2020 in connection with U.S. Appl. No. 16/190,959, 81 pages.
Cady et al., “Intraocular Pseudophakic Contact Lens (IOPCL)-Based Telescopic Approach for Treating Age-Related Macular Degeneration (AMD) or Other Eye Disorders”, U.S. Appl. No. 17/332,533, filed May 27, 2021, 35 pages.
Examination Report dated Mar. 31, 2021 in connection with New Zealand Patent Application No. 755995, 3 pages.
Office Action dated Apr. 2, 2021 in connection with Chinese Patent Application No. 201880046413.X, 9 pages.
Notice of acceptance for patent application dated May 7, 2021 in connection with Australian Patent Application No. 2018301248, 31 pages.
Office Action dated Jul. 12, 2021 in connection with Australian Patent Application No. 2020239672, 4 pages.
European Search Report dated Jul. 16, 2021 in connection with European Patent Application No. 21161655.2, 5 pages.
Office Action dated Aug. 11, 2021 in connection with Australian Patent Application No. 2021200835, 2 pages.
Office Action dated Oct. 22, 2021 in connection with Canadian Patent Application No. 2,961,543, 5 pages.
Notice of Request for Submission of Argument dated Aug. 24, 2021 in connection with Korean Patent Application No. 10-2021-7018671, 12 pages.
European Search Report dated Sep. 2, 2021 in connection with European Patent Application No. 21168724, 7 pages.
International Search Report and Written Opinion of the International Searching Authority dated Oct. 7, 2021 in connection with International Patent Application No. PCT/US2021/037911, 9 pages.
Office Action dated Sep. 26, 2023 in connection with Korean Patent Application No. 10-2023-7028004, 29 pages.
Office Action dated Jul. 18, 2023 in connection with Japanese Patent Application No. 2022-170709, 7 pages.
Supplementary European Search Report dated Dec. 5, 2023 in connection with European Patent Application No. 20902943.8, 11 pages.
Examination Report No. 1 for Australian Patent Application No. AU2021245264 dated Sep. 20, 2022, 4 pages.
Examination Report No. 2 for Australian Patent Application No. AU2021245264 dated Nov. 23, 2022, 3 pages.
Decision to Grant a Patent for Japanese Patent Application No. 2021085035 dated Dec. 7, 2022, 4 pages.
Decision to Grant a Patent for Japanese Patent Application No. 2020501359 dated Nov. 29, 2022, 3 pages.
International Search Report dated Feb. 17, 2021 in connection with International Patent Application No. PCT/US2020/61099, 3 pages.
Written Opinion of the International Searching Authority dated Feb. 17, 2021 in connection with International Patent Application No. PCT/US2020/61099, 6 pages.
Japanese Patent Office, Office Action dated May 25, 2022 in connection with Japanese Patent Application No. 2021-085035, 4 pages.
Japanese Patent Office, Office Action dated Jul. 20, 2022 in connection with Japanese Patent Application No. 2020-501359, 4 pages.
Office Action dated Jan. 3, 2022 in connection with U.S. Appl. No. 17/011,975, 20 pages.
Office Action dated Oct. 12, 2021 in connection with Mexican Patent Application No. MX/a/2017/003760, 7 pages.
Related Publications (1)
Number Date Country
20210282920 A1 Sep 2021 US
Provisional Applications (2)
Number Date Country
63057738 Jul 2020 US
62053771 Sep 2014 US
Continuations (2)
Number Date Country
Parent 16190959 Nov 2018 US
Child 17011975 US
Parent 14860629 Sep 2015 US
Child 16190959 US
Continuation in Parts (5)
Number Date Country
Parent 17011975 Sep 2020 US
Child 17332577 US
Parent 16717304 Dec 2019 US
Child 17011975 US
Parent 16398627 Apr 2019 US
Child 16717304 US
Parent 15646254 Jul 2017 US
Child 16398627 US
Parent 14860629 Sep 2015 US
Child 15646254 US